Author: admin

“Charcot Marie Tooth Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Charcot Marie Tooth Disease Market.

The Charcot Marie Tooth Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Charcot Marie Tooth Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Charcot Marie Tooth Disease treatment therapies with a considerable amount of success over the years.

• Charcot Marie Tooth Disease companies working in the treatment market are DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharmaceutical, ENCell, HELIXMITH, Pharnext SA, MedDay Pharmaceuticals, and others, are developing therapies for the Charcot Marie Tooth Disease treatment

• Emerging Charcot Marie Tooth Disease therapies in the different phases of clinical trials are- DTx-1252, HDAC6i, Research programme: GABAB PAM, IFB-088, CKD-510, EN001, Engensis, PXT3003, MD1003, and others are expected to have a significant impact on the Charcot Marie Tooth Disease market in the coming years.

• In June 2025, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the first patient has been dosed in its first-in-human clinical trial evaluating VCA-894A, an antisense oligonucleotide (ASO) therapy, for a rare IGHMBP2 gene variant causing Charcot-Marie-Tooth disease Type 2S (CMT2S). The patient, diagnosed at age five, has this rare inherited neuromuscular disorder, which progressively causes muscle weakness and loss of motor function. CMT2S affects fewer than 1 in 1,000,000 people globally, with its severity and symptoms varying based on the diverse genetic variants linked to CMT disease.

• In May 2025, Augustine Therapeutics NV (“Augustine”), a biotechnology company developing novel therapies for neuromuscular, neurodegenerative, and cardio-metabolic diseases by inhibiting the cytosolic Histone DeACetylase 6 (HDAC6) enzyme, announced that the first patient has been dosed in its Phase I clinical trial of lead candidate AGT-100216, the first peripherally restricted, selective HDAC6 inhibitor.

• In March 2025, Actio Biosciences, a clinical-stage biotechnology company applying its one-to-many approach in genetics and precision medicine to develop therapies targeting shared underlying biology in rare and common diseases, announced that the first participant has been dosed in a Phase 1 healthy volunteer trial of its lead candidate, ABS-0871. This TRPV4 inhibitor is being developed for the treatment of TRPV4-positive Charcot-Marie-Tooth disease subtype 2C (CMT2C), a severe peripheral nerve disorder.

• In May 2025, Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company focused on developing transformative therapies for rare diseases, presented full 12-month clinical results along with new topline data at 18 and 24 months from the INSPIRE Phase 2/3 trial of govorestat (AT-007) for treating Sorbitol Dehydrogenase (SORD) Deficiency, a subtype of Charcot-Marie-Tooth (CMT) disease. The data were shared in an oral presentation at the Peripheral Nerve Society (PNS) 2025 Annual Meeting, held May 17-20, 2025, in Edinburgh, Scotland.

• In March 2025, ENCell, a prominent biopharmaceutical company specializing in cell and gene therapy CDMO services and innovative drug development, announced that its investigational drug EN001 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for treating Charcot-Marie-Tooth disease (CMT). CMT is an inherited neuromuscular disorder that leads to progressive muscle weakness and deformities in the hands and feet, and in severe cases, may result in vision and hearing impairments.

• In January 2025, Biotechnology company NMD Pharma announced that the US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its Charcot-Marie-Tooth (CMT) disease therapy, NMD670. Previously, NMD670 had received ODD from the FDA for generalized myasthenia gravis in September 2022. NMD670 is a small molecule inhibitor targeting the skeletal muscle-specific chloride ion channel CIC-1. In November 2024, NMD Pharma initiated the Phase 2 SYNAPSE-CMT trial, evaluating a twice-daily oral dose of NMD670 over 21 days in 80 adult patients with genetically confirmed CMT1 or CMT2 subtypes. CMT is a hereditary neuropathy affecting an estimated 136,000 individuals in the US and three million globally, causing muscle weakness, fatigue, and sensory deficits.

Charcot Marie Tooth Disease Overview

Charcot-Marie-Tooth disease, also known as hereditary motor and sensory neuropathy (HMSN), is a group of inherited neurological disorders that affect the peripheral nerves. These nerves are responsible for transmitting signals between the brain and spinal cord to the muscles, skin, and sensory organs, controlling movements and sensation in the arms and legs.

Get a Free Sample PDF Report to know more about Charcot Marie Tooth Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-pipeline-insight

Emerging Charcot Marie Tooth Disease Drugs Under Different Phases of Clinical Development Include:

• DTx-1252: DTx Pharma

• HDAC6i: Augustine therapeutics

• Research programme: GABAB PAM: Addex Therapeutics

• IFB-088: InFlectis BioScience

• CKD-510: Chong Kun Dang pharmaceutical

• EN001: ENCell

• Engensis: HELIXMITH

• PXT3003: Pharnext SA

• MD1003: MedDay Pharmaceuticals

Charcot Marie Tooth Disease Route of Administration

Charcot Marie Tooth Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Charcot Marie Tooth Disease Molecule Type

Charcot Marie Tooth Disease Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Charcot Marie Tooth Disease Pipeline Therapeutics Assessment

• Charcot Marie Tooth Disease Assessment by Product Type

• Charcot Marie Tooth Disease By Stage and Product Type

• Charcot Marie Tooth Disease Assessment by Route of Administration

• Charcot Marie Tooth Disease By Stage and Route of Administration

• Charcot Marie Tooth Disease Assessment by Molecule Type

• Charcot Marie Tooth Disease by Stage and Molecule Type

DelveInsight’s Charcot Marie Tooth Disease Report covers around 15+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Charcot Marie Tooth Disease product details are provided in the report. Download the Charcot Marie Tooth Disease pipeline report to learn more about the emerging Charcot Marie Tooth Disease therapies

Some of the key companies in the Charcot Marie Tooth Disease Therapeutics Market include:

Key companies developing therapies for Charcot Marie Tooth Disease are – Pharnext SA, MedDay Pharmaceuticals, HELIXMITH, ENCell, Chong Kun Dang Pharmaceutical, InFlectis BioScience, Addex Therapeutics, Augustine Therapeutics, DTx Pharma, and others.

Charcot Marie Tooth Disease Pipeline Analysis:

The Charcot Marie Tooth Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Charcot Marie Tooth Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Charcot Marie Tooth Disease Treatment.

• Charcot Marie Tooth Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Charcot Marie Tooth Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Charcot Marie Tooth Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Charcot Marie Tooth Disease drugs and therapies

Charcot Marie Tooth Disease Pipeline Market Drivers

• Increase in prevalence of Charcot Marie Tooth Disease, increase in Research and development Activities are some of the important factors that are fueling the Charcot Marie Tooth Disease Market.

Charcot Marie Tooth Disease Pipeline Market Barriers

• However, lack of FDA approved treatment, difficulty in diagnosis of the disease and other factors are creating obstacles in the Charcot Marie Tooth Disease Market growth.

Scope of Charcot Marie Tooth Disease Pipeline Drug Insight

• Coverage: Global

• Key Charcot Marie Tooth Disease Companies: DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharmaceutical, ENCell, HELIXMITH, Pharnext SA, MedDay Pharmaceuticals, and others

• Key Charcot Marie Tooth Disease Therapies: DTx-1252, HDAC6i, Research programme: GABAB PAM, IFB-088, CKD-510, EN001, Engensis, PXT3003, MD1003, and others

• Charcot Marie Tooth Disease Therapeutic Assessment: Charcot Marie Tooth Disease current marketed and Charcot Marie Tooth Disease emerging therapies

• Charcot Marie Tooth Disease Market Dynamics: Charcot Marie Tooth Disease market drivers and Charcot Marie Tooth Disease market barriers

Request for Sample PDF Report for Charcot Marie Tooth Disease Pipeline Assessment and clinical trials

Table of Contents

1. Charcot Marie Tooth Disease Report Introduction

2. Charcot Marie Tooth Disease Executive Summary

3. Charcot Marie Tooth Disease Overview

4. Charcot Marie Tooth Disease- Analytical Perspective In-depth Commercial Assessment

5. Charcot Marie Tooth Disease Pipeline Therapeutics

6. Charcot Marie Tooth Disease Late Stage Products (Phase II/III)

7. Charcot Marie Tooth Disease Mid Stage Products (Phase II)

8. Charcot Marie Tooth Disease Early Stage Products (Phase I)

9. Charcot Marie Tooth Disease Preclinical Stage Products

10. Charcot Marie Tooth Disease Therapeutics Assessment

11. Charcot Marie Tooth Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Charcot Marie Tooth Disease Key Companies

14. Charcot Marie Tooth Disease Key Products

15. Charcot Marie Tooth Disease Unmet Needs

16 . Charcot Marie Tooth Disease Market Drivers and Barriers

17. Charcot Marie Tooth Disease Future Perspectives and Conclusion

18. Charcot Marie Tooth Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Charcot Marie Tooth Disease Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pharnext SA, MedDay Pharmaceuticals, HELIXMITH, ENCell

“Congenital Hyperinsulinism Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Congenital Hyperinsulinism Market.

The Congenital Hyperinsulinism Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Congenital Hyperinsulinism Pipeline Report:

• Companies across the globe are diligently working toward developing novel Congenital Hyperinsulinism treatment therapies with a considerable amount of success over the years.

• Congenital Hyperinsulinism companies working in the treatment market are Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others, are developing therapies for the Congenital Hyperinsulinism treatment

• Emerging Congenital Hyperinsulinism therapies in the different phases of clinical trials are- CRN-04777, HM 15136, RZ358, Dasiglucagon, and others are expected to have a significant impact on the Congenital Hyperinsulinism market in the coming years.

• In October 2024, Zealand Pharma A/S (Nasdaq: ZEAL), a biotechnology company specializing in peptide-based medicines, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for Part 1 of the New Drug Application (NDA) for dasiglucagon. This application is for the prevention and treatment of hypoglycemia in pediatric patients aged 7 days and older with congenital hyperinsulinism (CHI) for up to three weeks of dosing.

• In September 2024, The US Food and Drug Administration (FDA) has removed the partial clinical holds on Rezolute’s RZ358 (ersodetug), allowing the drug to proceed with a Phase III trial for the treatment of hypoglycemia caused by congenital hyperinsulinism (HI). This regulatory decision enables the inclusion of US participants in the ongoing global sunRIZE study.

• In July 2024, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) announced today that it has acquired avexitide from Eiger BioPharmaceuticals, Inc. (Eiger). Avexitide has been investigated for its potential use in treating hyperinsulinemic hypoglycemia.

Congenital Hyperinsulinism Overview

Congenital Hyperinsulinism is a rare genetic disorder characterized by the excessive production and secretion of insulin by the beta cells in the pancreas. Insulin is a hormone responsible for regulating blood sugar levels by promoting the uptake of glucose into cells. In individuals with congenital hyperinsulinism, there is an abnormality in the regulation of insulin secretion, leading to hypoglycemia (low blood sugar).

Get a Free Sample PDF Report to know more about Congenital Hyperinsulinism Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/congenital-hyperinsulinism-pipeline-insight

Emerging Congenital Hyperinsulinism Drugs Under Different Phases of Clinical Development Include:

• CRN-04777: Crinetics Pharmaceuticals

• HM 15136: Hanmi Pharmaceutical

• RZ358: Rezolute

• Dasiglucagon: Zealand Pharma

Congenital Hyperinsulinism Route of Administration

Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Congenital Hyperinsulinism Molecule Type

Congenital Hyperinsulinism Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins

• Small molecule

• Monoclonal antibody

• Peptide

• Polymer

• Gene therapy

Congenital Hyperinsulinism Pipeline Therapeutics Assessment

• Congenital Hyperinsulinism Assessment by Product Type

• Congenital Hyperinsulinism By Stage and Product Type

• Congenital Hyperinsulinism Assessment by Route of Administration

• Congenital Hyperinsulinism By Stage and Route of Administration

• Congenital Hyperinsulinism Assessment by Molecule Type

• Congenital Hyperinsulinism by Stage and Molecule Type

DelveInsight’s Congenital Hyperinsulinism Report covers around 4+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Congenital Hyperinsulinism product details are provided in the report. Download the Congenital Hyperinsulinism pipeline report to learn more about the emerging Congenital Hyperinsulinism therapies

Some of the key companies in the Congenital Hyperinsulinism Therapeutics Market include:

Key companies developing therapies for Congenital Hyperinsulinism are – Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Crinetics Pharmaceuticals, and others.

Congenital Hyperinsulinism Pipeline Analysis:

The Congenital Hyperinsulinism pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Congenital Hyperinsulinism with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Congenital Hyperinsulinism Treatment.

• Congenital Hyperinsulinism key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Congenital Hyperinsulinism Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Congenital Hyperinsulinism market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Congenital Hyperinsulinism drugs and therapies

Congenital Hyperinsulinism Pipeline Market Drivers

• Increase in awareness of Congenital Hyperinsulinisms, increase in research and developmental activities are some of the important factors that are fueling the Congenital Hyperinsulinism Market.

Congenital Hyperinsulinism Pipeline Market Barriers

• However, high-cost associated with the disease, complications associated with insulin formulation and other factors are creating obstacles in the Congenital Hyperinsulinism Market growth.

Scope of Congenital Hyperinsulinism Pipeline Drug Insight

• Coverage: Global

• Key Congenital Hyperinsulinism Companies: Crinetics Pharmaceuticals, Hanmi Pharmaceutical, Rezolute, Zealand Pharma, and others

• Key Congenital Hyperinsulinism Therapies: CRN-04777, HM 15136, RZ358, Dasiglucagon, and others

• Congenital Hyperinsulinism Therapeutic Assessment: Congenital Hyperinsulinism current marketed and Congenital Hyperinsulinism emerging therapies

• Congenital Hyperinsulinism Market Dynamics: Congenital Hyperinsulinism market drivers and Congenital Hyperinsulinism market barriers

Request for Sample PDF Report for Congenital Hyperinsulinism Pipeline Assessment and clinical trials

Table of Contents

1. Congenital Hyperinsulinism Report Introduction

2. Congenital Hyperinsulinism Executive Summary

3. Congenital Hyperinsulinism Overview

4. Congenital Hyperinsulinism- Analytical Perspective In-depth Commercial Assessment

5. Congenital Hyperinsulinism Pipeline Therapeutics

6. Congenital Hyperinsulinism Late Stage Products (Phase II/III)

7. Congenital Hyperinsulinism Mid Stage Products (Phase II)

8. Congenital Hyperinsulinism Early Stage Products (Phase I)

9. Congenital Hyperinsulinism Preclinical Stage Products

10. Congenital Hyperinsulinism Therapeutics Assessment

11. Congenital Hyperinsulinism Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Congenital Hyperinsulinism Key Companies

14. Congenital Hyperinsulinism Key Products

15. Congenital Hyperinsulinism Unmet Needs

16 . Congenital Hyperinsulinism Market Drivers and Barriers

17. Congenital Hyperinsulinism Future Perspectives and Conclusion

18. Congenital Hyperinsulinism Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Congenital Hyperinsulinism Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Rezolute, Hanmi Pharma, Zealand Pharma, Crinetics Pharma

“Chronic Kidney Disease Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Kidney Disease Market.

The Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Kidney Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Chronic Kidney Disease treatment therapies with a considerable amount of success over the years.

• Chronic Kidney Disease companies working in the treatment market are Maze Therapeutics, Alebund Pharmaceuticals, AdAlta, Lisata Therapeutics, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AstraZeneca, Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others, are developing therapies for the Chronic Kidney Disease treatment

• Emerging Chronic Kidney Disease therapies in the different phases of clinical trials are- Research Program, AP 304, AD-214, CLBS201, Tirzepatide, HRS-1780, BI-685509, Baxdrostat, DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others are expected to have a significant impact on the Chronic Kidney Disease market in the coming years.

• In May 2025, Bayer announced a study aimed at evaluating the effectiveness of different doses of BAY3283142, when combined with standard CKD treatment, in reducing urinary albumin levels in participants with chronic kidney disease. The study will compare changes in the urine albumin-creatinine ratio (UACR) after 16 weeks between BAY3283142 and a placebo.

• In May 2025, AstraZeneca carried out a Phase IV trial to evaluate the efficacy and safety of dapagliflozin in preventing the progression of chronic kidney disease in adult patients in China.

• In June 2024, Novo Nordisk announced that the Phase III CLARION-CKD trial did not meet its primary endpoint and that it will record an impairment loss of approximately DKK 5.7 billion for the intangible asset ocedurenone in the second quarter of 2024.

• In May 2024, In the landmark FLOW trial, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrated substantial benefits in reducing the risk of major kidney disease, cardiovascular events, and mortality in patients with chronic kidney disease (CKD) and type 2 diabetes.

• In March 2024, Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Vafseo® (vadadustat) Tablets. This medication is indicated for the treatment of anemia resulting from chronic kidney disease (CKD) in adults undergoing dialysis for a minimum of three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor administered once daily, which triggers the body’s response to hypoxia to stimulate natural erythropoietin production, thereby managing anemia. Vafseo has received approval in 37 countries.

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. The kidneys are essential for filtering waste and excess fluids from the blood, which are then excreted in urine. When kidney function declines, waste products and fluid can build up in the body, leading to various health problems.

Get a Free Sample PDF Report to know more about Chronic Kidney Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight

Emerging Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

• Research Program: Maze Therapeutics

• AP 304: Alebund Pharmaceuticals

• AD-214: AdAlta

• CLBS201: Lisata Therapeutics

• Tirzepatide: Eli Lilly and Company

• HRS-1780: Shandong Suncadia Medicine

• BI-685509: Boehringer Ingelheim

• Baxdrostat: AstraZeneca

• DDO-3055: Jiangsu HengRui Medicine

• DISC: 0974 Disc Medicine

• SSS 17: 3SBio

• AND017: Kind Pharmaceuticals

• Pegol-Sihematide: Jiangsu Hansoh Pharmaceuticals

• Efepoetin alfa: Genexine

Chronic Kidney Disease Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral

• Parenteral

• Intravenous

• Subcutaneous

• Topical

Chronic Kidney Disease Molecule Type

Chronic Kidney Disease Products have been categorized under various Molecule types, such as

• Monoclonal Antibody

• Peptides

• Polymer

• Small molecule

• Gene therapy

Chronic Kidney Disease Pipeline Therapeutics Assessment

• Chronic Kidney Disease Assessment by Product Type

• Chronic Kidney Disease By Stage and Product Type

• Chronic Kidney Disease Assessment by Route of Administration

• Chronic Kidney Disease By Stage and Route of Administration

• Chronic Kidney Disease Assessment by Molecule Type

• Chronic Kidney Disease by Stage and Molecule Type

DelveInsight’s Chronic Kidney Disease Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

Further Chronic Kidney Disease product details are provided in the report. Download the Chronic Kidney Disease pipeline report to learn more about the emerging Chronic Kidney Disease therapies

Some of the key companies in the Chronic Kidney Disease Therapeutics Market include:

Key companies developing therapies for Chronic Kidney Disease are – FibroGen Inc, FortuneRock (China) Ltd, General Biologics Inc, Genexine Inc, Great Bay Bio Holdings Ltd, GSK plc, 3SBio Inc, Akebia Therapeutics Inc, Avesthagen Ltd, Biocad, Chong Kun Dang Pharmaceutical Corporation, Dong-A Socio Holdings Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Liminal BioSciences Inc, Panacea Biotec Ltd, Panion & Bf Biotech Inc, PharmaEssentia Corp, PhytoHealth Corp, Jiangsu Hansoh Pharmaceutical Group Co Ltd, UBI Pharma Inc, Uni-Bio Science Group Ltd, Xenetic Biosciences Inc, Zosano Pharma Corp, Shanghai Chemo Wanbang Biopharma Co Ltd, SunBio Inc, HEC Pharma Co Ltd, HK inno.N Corp, Imagine Pharma LLC, InSilico Medicine, Japan Tobacco Inc, Jecho Biopharmaceuticals Co Ltd, Zydus Lifesciences Ltd, and others.

Chronic Kidney Disease Pipeline Analysis:

The Chronic Kidney Disease pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.

• Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Kidney Disease drugs and therapies

Chronic Kidney Disease Pipeline Market Drivers

• Increase in the geriatric population with a higher risk of renal anemia due to age-related renal issues, increase in research and developmental activities are some of the important factors that are fueling the Chronic Kidney Disease Market.

Chronic Kidney Disease Pipeline Market Barriers

• However, high-cost associated with the disease, side effects associated with the disease and other factors are creating obstacles in the Chronic Kidney Disease Market growth.

Scope of Chronic Kidney Disease Pipeline Drug Insight

• Coverage: Global

• Key Chronic Kidney Disease Companies: Maze Therapeutics, Alebund Pharmaceuticals, AdAlta, Lisata Therapeutics, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AstraZeneca, Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others

• Key Chronic Kidney Disease Therapies: Research Program, AP 304, AD-214, CLBS201, Tirzepatide, HRS-1780, BI-685509, Baxdrostat, DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others

• Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies

• Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers

Request for Sample PDF Report for Chronic Kidney Disease Pipeline Assessment and clinical trials

Table of Contents

1. Chronic Kidney Disease Report Introduction

2. Chronic Kidney Disease Executive Summary

3. Chronic Kidney Disease Overview

4. Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment

5. Chronic Kidney Disease Pipeline Therapeutics

6. Chronic Kidney Disease Late Stage Products (Phase II/III)

7. Chronic Kidney Disease Mid Stage Products (Phase II)

8. Chronic Kidney Disease Early Stage Products (Phase I)

9. Chronic Kidney Disease Preclinical Stage Products

10. Chronic Kidney Disease Therapeutics Assessment

11. Chronic Kidney Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Kidney Disease Key Companies

14. Chronic Kidney Disease Key Products

15. Chronic Kidney Disease Unmet Needs

16 . Chronic Kidney Disease Market Drivers and Barriers

17. Chronic Kidney Disease Future Perspectives and Conclusion

18. Chronic Kidney Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharma